Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022-Reference-Cited by-同舟云学术

Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022

Published:2023-05-29 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Hall Victoria J^ORCID,Insalata Ferdinando,Foulkes Sarah^ORCID,Kirwan Peter^ORCID,Sparkes Dominic,Atti Ana^ORCID,Cole Michelle^ORCID,Lacy Elen de,Price Lesley,Corrigan Diane,Brown Colin S,Islam Jasmin,Charlett Andre^ORCID,Hopkins Susan^ORCID,

Abstract

ABSTRACTThird doses of COVID-19 vaccines were widely deployed following primary vaccine course waning and emergence of the Omicron-variant. We investigated protection from third-dose vaccines and previous infection against SARS-CoV-2 infection during Delta-variant and Omicron-variant (BA.1 & BA.2) waves in our frequently PCR-tested cohort of healthcare-workers.

Publisher

Cold Spring Harbor Laboratory

Reference40 articles.

1. JCVI. JCVI statement regarding a COVID-19 booster vaccine programme for winter 2021 to 2022. https://www.gov.uk/government/publications/jcvi-statement-september-2021-covid-19-booster-vaccine-programme-for-winter-2021-to-2022/jcvi-statement-regarding-a-covid-19-booster-vaccine-programme-for-winter-2021-to-2022#fn:1, 2021.

2. Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

3. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar

4. Lauring AS , Tenforde MW , Chappell JD , et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ 2022; 376: e069761.

5. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection;New England Journal of Medicine,2022